Literature DB >> 28823952

Time is vision in recurrent optic neuritis.

Esther Osinga1, Bob van Oosten2, Willemien de Vries-Knoppert3, Axel Petzold4.   

Abstract

In optic neuritis (ON) inflammation precedes onset of demyelination and axonal loss. The anti-inflammatory properties of corticosteroids may be most effective in the early inflammatory phase, but rapid patient recruitment remains a logistic challenge. The aim of the study was to review the effect of time to initiation of treatment on visual outcome in recurrent ON. A retrospective case note review of patients known to our centre with recurrent ON. The primary clinical outcome was change of best corrected high contrast visual acuity (BCVA). The secondary outcome was the change of optical coherence tomography (OCT) thickness of the peripapillary retinal nerve fibre layer (pRNFL) and macular ganglion cell layer (mGCL) from baseline and after a minimum of 3months following the episode of recurrent ON. Of 269 patients with a previous episode of ON, 54 experienced recurrent ON. In total 40 OCT documented episodes of relapsing ON were captured in 19 patients. Treatment within <2days led to better recovery of the BCVA (+0.02) and mGCL (-2.4µm) if compared to delayed treatment (BCVA -0.2, p=0.036, mGCL -25.6µm, p=0.019) or no corticosteroids treatment (BCVA -0.2, p=0.045, GCL -5.0µm, p=0.836). These data suggest a beneficial effect of hyperacute corticosteroid treatment. A pragmatic approach for a prospective treatment trial should consider patients with recurrent ON for logistic reasons.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Corticosteroids; Optical coherence tomography; Recurrent optic neuritis; Visual acuity

Mesh:

Substances:

Year:  2017        PMID: 28823952     DOI: 10.1016/j.brainres.2017.08.012

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  3 in total

1.  Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?

Authors:  Hadas Stiebel-Kalish; Mark Andrew Hellmann; Michael Mimouni; Friedemann Paul; Omer Bialer; Michael Bach; Itay Lotan
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-05-21

Review 2.  Treatment and Relapse Prevention of Typical and Atypical Optic Neuritis.

Authors:  George Saitakis; Bart K Chwalisz
Journal:  Int J Mol Sci       Date:  2022-08-29       Impact factor: 6.208

Review 3.  Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence.

Authors:  Axel Petzold; Tasanee Braithwaite; Bob W van Oosten; Lisanne Balk; Elena H Martinez-Lapiscina; Russell Wheeler; Nils Wiegerinck; Christiaan Waters; Gordon T Plant
Journal:  J Neurol Neurosurg Psychiatry       Date:  2019-11-18       Impact factor: 10.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.